Dr. Jeffery Venner is currently a PGY-5 Gastroenterology Fellow at the University of Manitoba (Winnipeg, Canada). He completed his core Internal Medicine training at the University of Manitoba in 2022, and he received his MD (2018) from the University of Queensland (Brisbane, Australia). Dr. Venner also has a MSc (2011) in Experimental Medicine with a focus in molecular immunology and a BSc (Honors in Immunology and Infection, 2008), both from the University of Alberta (Edmonton, Canada). Upon completion his gastroenterology training, Dr. Venner will undertake a postdoctoral research fellowship and an advanced clinical fellowship in inflammatory bowel disease (IBD). Dr. Venner’s research interests are in combining various high-throughput molecular assays (e.g. microarrays, spatial transcriptomics) with clinical variables (e.g. endoscopy and histology) to improve our understanding of disease phenotypes and mechanisms, particularly in IBD. Dr. Venner is the recipient of several awards, including from CIHR, and is well on his way to becoming a well published clinician scientist, with publications already in Circulation, Gastroenterology Report, JCI Insight, and the American Journal of Transplantation.

Affiliations:
Section of Gastroenterology
Departments of Internal Medicine
Max Rady College of Medicine, Rady Faculty of Health Sciences
University of Manitoba
Dr Singh is a clinician scientist with research interests in assessing and improving health care outcomes in IBD and gastrointestinal cancers (in particular colorectal cancer [CRC]. He is the Director of Research of the Canadian IBD Research Consortium (CIRC), a member of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC), and a co-author of the Burden of IBD Reports for Crohn’s and Colitis Canada. He has lead studies assessing health care outcomes among individuals with IBD, including skin cancers, cervical cancer precursors, colorectal cancer, screening for cancers, risk of clostridium difficile infections, educational outcomes among those with IBD and care of elderly with IBD. He has a large clinical practice of individuals with IBD.

Affiliations:
Associate Professor of Medicine
Departments of Internal Medicine, Biochemistry and Medical Genetics, and Community Health Sciences
Max Rady College of Medicine,
College of Rehabilitation Sciences
Rady Faculty of Health Sciences
University of Manitoba
Adjunct Scientist, Paul Albrechtsen Research Institute CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada

MANAGEMENT OF CLOSTRIDIOIDES DIFFICILE IN IBD PATIENTS

Introduction
Clostridoides difficile (C. difficile) is an anaerobic, spore-forming, Gram-positive bacterium. C. difficile is the most frequently reported nosocomial pathogen. C. difficile is also the most commonly identified pathogen associated with antibiotic-associated diarrhea, responsible for up to 30% of antibiotic-associated diarrhea. Spores are transmitted via the fecal-oral route, and acquisition of C. difficile in the healthcare setting is generally by contaminated hands or surfaces. C. difficile has two monoglycosyltransferase virulence factors that are responsible for damage to the intestinal mucosa, enterotoxin A (TcdA) and cytotoxin B (TcdB). These two enzymes enter intestinal epithelium through receptor-mediated endocytosis and irreversibly inactive Rho GTPases. This ultimately disrupts the cytoskeleton and tight junctions, resulting in a loss of parenchymal polarity and eventual apoptosis.

A population-based study from Manitoba reported that individuals with inflammatory bowel disease (IBD) have a 4.8-fold increased risk of laboratory confirmed C. difficile infection (CDI) compared to individuals without IBD, with no difference in rates between those with ulcerative colitis (UC) or Crohn’s disease (CD). Among individuals with IBD, exposure to corticosteroids; use of anti-TNF agents; use of metronidazole; hospitalizations; numerous ambulatory care visits; shorter duration of IBD; and numerous comorbidities are associated with an increased risk of CDI. The risk of CDI is increased among individuals of all ages with IBD. The incidence rate of hospitalization with CDI in a Canadian multi-provincial population-based incident cohort of children with IBD was reported to be 49.06 (95% CI 39.40-61.08) per 10,000 person-years and was nearly 70-fold that of age- and sex-matched children without IBD. The reasons why IBD patients are more susceptible to CDI are not fully understood, but some possible factors include: frequent use of antibiotics and immunosuppressive drugs; increased exposure to healthcare settings where C. difficile is prevalent; altered gut microbiota; compromised mucosal barrier function due to inflammation; and genetic susceptibility.
Among patients with IBD, CDI is associated with worse clinical outcomes compared to individuals without IBD, including increased emergency room visits, longer hospitalizations, higher rates of colectomy, and increased mortality. CDI may mimic an IBD flare and can precipitate an IBD flare. Given the clinical overlap between CDI and IBD exacerbations (e.g., increased frequency of loose stools, abdominal pain), it is difficult to differentiate CDI versus colonic colonization in patients with active IBD who test positive for *C. difficile*. C. difficile colonization occurs in up to 15% of healthy adults and more than 20% of hospitalized adults. In a prospective study, *C. difficile* colonization was higher among IBD patients (8.2%) in remission with no recent hospitalizations or recent exposure to corticosteroids, immunomodulators or antibiotics compared to healthy controls (1.0%).

**Diagnosing Clostridioides difficile Infection**

Testing and treatment for *C. difficile* colonization is not recommended. Rather, testing for *C. difficile* should occur in patients where there is clinical suspicion for CDI (e.g., frequent and loose stools, abdominal pain, leukocytosis). Therefore, anyone with known IBD presenting with an acute flare associated with diarrhea should undergo testing for *C. difficile*. All diagnostic tests have been validated for use on unformed stool only; as a result, most laboratories will not process formed stool.

The Infectious Disease Society of America (IDSA) and the American College of Gastroenterology (ACG) recommend multistep testing algorithms to diagnose CDI. However, use of a multistep testing algorithm can fail to differentiate symptomatic CDI from asymptomatic colonization among individuals with IBD with symptoms due to IBD.

Commercially available tests include nucleic acid amplification tests (NAAT), enzyme immunoassays (EIA), toxigenic culture, and next-generation sequencing (NGS). NAAT is a PCR that tests for the presence of toxin genes A and B. NAAT is regarded to have excellent sensitivity (up to 100%), but a specificity of 87% with a positive-predictive value of 45%; therefore, there is risk of overdiagnosis in the setting of colonization. The EIA for the presence of toxin in stool are regarded to have lower sensitivity but improved specificity compared to NAAT. Ultrasensitive protein-based stool tests have been developed that have improved diagnostic accuracy for CDI; however, they are not yet commercially available. Certain laboratories may use EIA to detect stool glutamate dehydrogenase (GDH). However, this enzyme is produced by both toxigenic and nontoxigenic strains of *C. difficile*, therefore, a second confirmatory test is required.

Due to the issues with differentiating CDI vs colonization, a multistep algorithm is recommended by the ACG, first using a highly sensitive NAAT or GDH test, followed by a more specific toxin EIA if the first test is positive. If both tests are positive, a diagnosis of CDI is reliably made. A problem arises when there is discordance between two tests. As toxin EIA is less sensitive, GDH positive, toxin negative can result in a false negative, where a CDI exists. The ACG guideline points out “Because no test is perfect, the diagnosis and decision to treat is a clinical one. Treatment should not be withheld when there is high clinical suspicion, based on laboratory testing alone”. Therefore, a positive GDH with a negative EIA toxin test requires treatment in selected cases with severe symptoms and a high index of suspicion for CDI in IBD patients.

**Treatment of Clostridioides difficile Infection**

Following the diagnosis of a CDI in an individual with IBD involves treating the infection with antibiotics and optimizing management of the patient's immunosuppression. The IDSA and ACG consider vancomycin or fidaxomycin as first-line antibiotics for non-severe or severe diseases (white blood count ≥15,000 cells/mL or serum creatinine >1.5x above baseline). Vancomycin is dosed at 125 mg orally four times/day for 10 days, and fidaxomycin is dosed at 200 mg orally twice daily for 10 days. Vancomycin is generally preferred as the first-line antibiotic as fidaxomycin is much more expensive. However, fidaxomycin is associated with lower rates of CDI relapse and some cost-effectiveness analyses do favor fidaxomycin over vancomycin.

There are limited data and randomized, controlled trials concerning treatment-specific regimens for CDI in individuals with IBD. In general, metronidazole is not recommended as monotherapy, and a prolonged course of vancomycin (14 days instead of 10 days) is favoured. Fidaxomycin is also deemed a reasonable option. In the setting of a suspected or confirmed IBD flare with concurrent CDI, immunosuppressive therapy should not be held; conversely escalation of immunotherapy should be considered in those with no symptomatic improvement after three days of CDI treatment.

For fulminant CDI, defined as the presence of hypotension or shock, ileus, or megacolon, vancomycin 500 mg four times daily (orally or by nasogastric tube) is recommended. Vancomycin can be administered rectally as an enema if enteral administration is contraindicated and, in such cases, intravenous metronidazole 500 mg every eight hours should be added in addition to rectal vancomycin.

*C. difficile* infection recurrence is defined as an episode of CDI occurring within 12 weeks of a previous CDI. For the first recurrent CDI, it is recommended that the treatment regimen be modified from the first, as follows: (1) vancomycin 125 mg orally four times daily for 10 days if metronidazole was used for the initial episode; (2) pulsed vancomycin plus taper (125 mg orally four times daily for 10-14 days, followed by twice daily for one week, then once daily for one week, then every two or three days for two to eight weeks if standard vancomycin dosing was used for the initial CDI; or (3) fidaxomycin 200 mg orally twice daily for 10 days if standard vancomycin dosing was used for the initial CDI. For a second recurrence or any subsequent recurrence thereafter, vancomycin pulse
and taper or standard fidaxomicin are recommended, as outlined above. Standard 10-day dosing of vancomycin followed by rifaximin 400 mg three times daily for 20 days is also an option. However, all of these treatment regimens for the second CDI and recurrence thereafter is based on low quality of evidence and therefore is backed by weak strength of recommendation (Table 1).12

Other options for the treatment of CDI recurrence include bezlotoxumab, a monoclonal antibody targeting cytotoxin B (TcdB), and fecal microbiota transplantation (FMT). The ACG recommends reserving bezlotoxumab for individuals experiencing at least their second episode of CDI in the past six months, in those aged 65 or over, along with an additional risk factor, i.e., immunocompromised or severe CDI.11

FMT is has been shown to be beneficial in preventing CDI recurrence in IBD patients.11 The ACG recommends that FMT be considered for patients with severe or fulminant CDI that is refractory to antibiotics, or for patients experiencing their second or further recurrence of CDI. It can be considered in IBD patients with their first CDI recurrence.11 FMT is administered through a colonoscopy and should be combined with an antibiotic regimen as described above. Toxic megacolon is not considered an absolute contraindication to the administration of a FMT.11 The colonoscope should be carefully advanced beyond the splenic flexure, and FMT repeated every 3-5 days until pseudomembrane resolution or discharge from hospital. Vowst™ is an orally administered fecal microbiota product that is FDA approved but not yet available in Canada. It is a capsule composed of purified Firmicutes spores from healthy donors, and is approved for CDI recurrence that is unresponsive to antibiotics.18

Additional Considerations
Probiotics are not recommended for the prevention of CDI or recurrent CDI due to a lack of conclusive evidence; this has been previously reviewed in detail.11 Follow-up testing or so-called test of cures should not be done where there has been adequate treatment and symptom resolution as there can be clinically irrelevant toxin shedding for up to four weeks postinfection. Furthermore, there is insufficient evidence to suggest that proton pump inhibitors (PPIs) should be discontinued as a measure for preventing CDI.11,12 C. difficile enteritis and pouchitis are rarely reported entities; however, C. difficile testing can be considered in IBD patients who have undergone colectomy and are unresponsive to conventional treatment for their underlying IBD.

![Table 1. First line drug regimens for the management of CDI in IBD; courtesy of Harminder Singh, MD and Jeffery M. Venner, MD](image)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dosing regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>First CDI episode</td>
<td>125 mg orally four times daily for 14 days</td>
</tr>
<tr>
<td>1. Vancomycin</td>
<td>200 mg orally twice daily for 10 days</td>
</tr>
<tr>
<td>2. Fidaxomicin</td>
<td>pulsed + taper (125 mg orally qid for 14 days, followed by bid for one week, then once daily for one week, then every two or three days for two to eight weeks if standard vancomycin dosing was used for initial CDI)</td>
</tr>
<tr>
<td>First CDI Recurrence (episode of CDI occurring within 12 weeks of a previous CDI)</td>
<td>200 mg orally bid for 10 days</td>
</tr>
<tr>
<td>1. Vancomycin</td>
<td>200 mg orally bid for 10 days</td>
</tr>
<tr>
<td>2. Fidaxomicin</td>
<td>pulsed + taper (125 mg orally qid for 14 days, followed by bid for one week, then once daily for one week, then every two or three days for two to eight weeks)</td>
</tr>
<tr>
<td>Second CDI Recurrence (or any subsequent recurrence thereafter)*</td>
<td>Standard 14-day dosing (vancomycin) followed by 400 mg tid for 20 days (rifaximin)</td>
</tr>
<tr>
<td>1. Vancomycin</td>
<td>200 mg orally bid for 10 days</td>
</tr>
<tr>
<td>2. Fidaxomicin</td>
<td>3. Vancomycin + rifaximin</td>
</tr>
</tbody>
</table>

* Low strength of evidence for these treatment regimens.
**Clinical Pearls**

- C. difficile occurs much more commonly among people with IBD
- C. difficile Infection is associated with worse outcomes among people with IBD
- Individuals with colonic IBD with flare symptoms should be evaluated for C. difficile infection
- Vancomycin is the drug of choice for treating the first episode of C. difficile infection
- Metronidazole should no longer be used to treat C. difficile Infections among those with IBD
- Multistep testing algorithms (i.e., include both a highly sensitive and a highly specific assay) should be used to diagnose CDI. However, as noted by the ACG, clinicians should also be aware that “Because no test is perfect, the diagnosis and decision to treat is a clinical one. Treatment should not be withheld when there is high clinical suspicion based on laboratory testing alone”.

**Correspondence:**
Dr. Harminder Singh
Email: Harminder.Singh@umanitoba.ca

**Financial Disclosures:**
**H.S.: Advisory boards/Consultation:** Abbvie Canada, Amgen Canada, Roche Canada, Sandoz Canada, Organon Canada, Eli Lilly Canada, Takeda Canada, Pendopharm Inc, and Guardant Health, Inc

**Research funding:** Pfizer

**J.V.:** None declared

**References**